Comparing atrial fibrillation guidelines: Focus on stroke prevention, bleeding risk assessment and oral anticoagulant recommendations

Clinical practice in atrial fibrillation (AF) patient management is constantly evolving. Non-vitamin K antagonist oral anticoagulants (NOACs) showed a favorable risk-benefit profile as compared to warfarin [1] and their prescription is encouraged by current AF guidelines [2–6] whenever appropriate.